It has been nearly a year and a half since my previous Checkpoint Therapeutics, Inc. (CKPT) article. Then, I highlighted the company's flagship candidate, cosibelimab, or "Cosi," and its potential ...

Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Checkpoint Therapeutics recently gained approval for cosibelimab, a PD-L1 inhibitor for advanced cSCC, but faces stiff competition and financial challenges. CKPT's pipeline includes cosibelimab ...

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has expanded its immuno-oncology footprint. The deal, announced earlier ...

WILLIAM GARRETT GRAY, the Chief Financial Officer of $CKPT, sold 74,110 shares of the company on 02-06-2025 for an estimated $271,983. We received data on the trade ...

Biotech, Inc. Fortress, a 10% owner of $CKPT, sold 100,000 shares of the company on 05-29-2025 for an estimated $129,000. We received data on the trade from a recent ...

CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders. March 10, 2025 08:05 AM Eastern Daylight Time.

Review the current valuation for Checkpoint Therapeutics Inc (CKPT:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Checkpoint Therapeutics, Inc. (CKPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...

Review Checkpoint Therapeutics Inc (CKPT:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.